The research suggests that a weekly injection of a higher semaglutide dose (7.2 mg) may lead to greater therapeutic benefits for patients with obesity and type 2 diabetes compared to current dosages.
the studies, conducted across different countries and including participants from various nationalities, revealed that the 7.2 mg dose of semaglutide resulted in an average weight loss of 18.7% compared to a placebo. Approximately half of the patients experienced a weight loss of 20% or more during the study period.
However, the higher dose was associated with more frequent and pronounced side effects, particularly gastrointestinal issues such as nausea, vomiting, and constipation, compared to the placebo group.
analysis indicates that the majority of weight loss achieved with semaglutide was attributable to a reduction in body fat. Further research is needed to determine if the higher degree of weight loss also leads to a loss of muscle mass.
It's important to note that the 7.2 mg dose used in these studies is substantially higher than the currently approved maximum dose of 2.0-2.4 mg, which has undergone rigorous safety testing.